Bioprocessing International (BPI) West
Enhancing Genome Editing Capabilities: Unveiling the Advantages of Cas-CLOVER over CRISPR/Cas9
Speaker: Corey Brizzee, Director, Gene Editing, Demeetra
Abstract
Cas-CLOVER is an advanced CRISPR/Cas9 alternative offering higher targeted integration efficiency, larger transgene capacity (≥20 kb), and superior FTO. Unlike CRISPR/Cas9, which has low knock-in efficiency and off-target effects, Cas-CLOVER’s dimeric system and Clo051 nuclease enhance precision. It achieves 3x higher knock-in rates, making it ideal for cell line development (CLD) and complex biologics like bi- and tri-specific antibodies.